Nutriband Inc.

NASDAQ
NTRB
paper.types.company
Rentabilité sur six mois: -8.45%
Rendement en dividendes: 0%
Secteur: Healthcare

Calendrier des promotions Nutriband Inc.

Calendrier avancé Graphique simple
Financial Markets by TradingView

À propos de l'entreprise Nutriband Inc.

Nutriband Inc. develops a portfolio of transdermal pharmaceutical products. Its lead product in development is AVERSA fentanyl, an abuse deterrent fentanyl transdermal system that provides clinicians and patients with an extended-release transdermal fentanyl product for use in managing chronic pain requiring around the clock opioid therapy. The company also develops other products, which include AVERSA buprenorphine and AVERSA methylphenidate; exenatide for type 2 diabetes; and follicle stimulating hormone for infertility. It has a license agreement with Rambam Med-Tech Ltd.

plus de détails
for the development of the RAMBAM Closed System Transfer Devices; and Kindeva Drug Delivery, L.P. to develop AVERSAL Fentanyl based on its proprietary AVERSAL abuse deterrent transdermal technology. The company was incorporated in 2016 and is headquartered in Orlando, Florida.
Ajouter à la liste de comparaison
Ajouter à la liste de surveillance
Ajouter au portefeuille
Ajouter un avis de prix

Paramètres de base

IPO date
2017-11-30
ISIN
US67092M2089
Industry
Biotechnology
Sector
Health Care
Валюта
usd
Валюта отчета
usd
Сайт
lien
Tous les paramètres

Grade

Sous-estimation
Nom Signification Grade
P/S 10.39 1
P/BV 3.37 5
P/E 0 0
Efficacité
Nom Signification Grade
ROA -64.63 0
ROE -73.08 0
ROIC 0 0
Dividendes
Nom Signification Grade
Rendement en dividendes 0 0
DSI 0 0
Croissance moyenne du dividende 0 0
Devoir
Nom Signification Grade
Debt/EBITDA -0.0471 10
Debt/Ratio 0.0321 10
Debt/Equity 0.0375 10
Impulsion de croissance
Nom Signification Grade
Rentabilité Revenue, % 126.65 10
Rentabilité Ebitda, % 311.39 10
Rentabilité EPS, % 127.86 10
Plus de détails

paper.price.prices

Prix Common.min. Common.max. Changement paper.changes_in_industry paper.changes_in_index
common.calendar.number_days.1 7.15 $ 0 $ 0 $ 0 % 0 % 0 %
common.calendar.number_days.7d 7.6 $ 7.15 $ 7.6 $ -5.92 % 0 % 0 %
common.calendar.number_days.30d 5.48 $ 5.36 $ 8.18 $ 30.47 % 0 % 0 %
common.calendar.number_days.90d 4.72 $ 4.72 $ 8.18 $ 51.48 % 0 % 0 %
common.calendar.number_days.180d 7.81 $ 3.85 $ 9.9 $ -8.45 % 0 % 0 %
common.calendar.number_days.1y 4.48 $ 3.84 $ 9.9 $ 59.6 % 0 % 0 %
common.calendar.number_days.3y 4.1 $ 1.93 $ 9.9 $ 74.39 % 0 % 0 %
common.calendar.number_days.5y 22 $ 1.93 $ 31 $ -67.5 % 0 % 0 %
common.calendar.number_days.10y 0 $ 1.65 $ 39.5 $ 0 % 0 % 0 %
common.calendar.number_days.ytd 7.12 $ 4.07 $ 9.9 $ 0.42 % 0 % 0 %

Principaux propriétaires

Entreprises similaires

P/E & P/BVEV/Ebitda & Debt/Ebitda


Gestion d'entreprise

Superviseur Titre d'emploi Paiement Année de naissance
Mr. Serguei Melnik Founder, President, Company Secretary & Executive Chairman of the Board 175k 1974 (51 année)
Mr. Gareth Sheridan Founder, CEO & Director 175k 1990 (35 années)
Mr. Gerald Goodman CFO & Chief Accounting Officer 140k 1948 (77 années)
Dr. Alan Smith Ph.D. COO & President of 4P Therapeutics 159k 1966 (59 années)
Dr. Jeffrey Patrick Pharm.D. Chief Scientific Officer N/A 1970 (55 années)
Mr. Tyler Overk Head of Active Intelligence N/A 1984 (41 année)
Mr. Michael Myer President of Pocono Pharmaceutical 40.6k 1985 (40 années)

Informations sur l'entreprise

Adresse: United States, Orlando. FL, 121 South Orange Avenue - Ouvrir dans google maps, Ouvrir les cartes yandex
Site web: https://nutriband.com